Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors

Inclusion Criteria:

- Pathologic (histologic or cytologic) confirmation of metastatic or locally advanced
solid tumor.

- Patients who have experienced disease progression after receiving appropriate
standard / approved chemotherapy and for whom no further standard or palliative
treatment measures exist, or who have chosen to decline standard or palliative
treatment.

- One or more tumors measurable by RECIST criteria.

- Karnofsky performance status ≥ 70%.

- Recovery from any toxic or other effects of all previous therapy, including
radiation, chemotherapy and surgery.

- Negative serum or urine pregnancy test result in women of childbearing potential.

- For men and women of child-producing potential, agreement to use effective
contraception (hormonal or barrier birth control or abstinence) from the time of
screening before study entry and throughout study participation.

Exclusion Criteria:

- Brain metastasis.

- New York Heart Association Class III or IV cardiac disease, myocardial infarction, or
cardiac arrhythmia requiring medical therapy.

- Known allergy to hyaluronidase.

- Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other
conditions including psychiatric illness) that could compromise protocol objectives
in the opinion of the Investigator and/or the Sponsor.

- Women currently breast feeding.

- Concurrent participation in any other interventional therapeutic study.